Adaptive Biotechnologies provided bullish 2026 guidance driven by growth in its minimal residual disease (MRD) business, projecting 22% year‑over‑year revenue growth for MRD at the midpoint and expecting ClonoSeq test volume to rise about 30%. The Seattle‑based immune‑sequencing firm attributed momentum to wider clinical adoption of blood‑based MRD testing, deeper penetration into community settings, and expanded EMR integration. Management also signaled higher average selling prices tied to upcoming payor renegotiations and increased trial services demand. Adaptive’s outlook frames MRD as a scalable commercial engine for diagnostic companies and could accelerate payor discussions about MRD as a clinical endpoint. Competitors and collaborators in oncology diagnostics will monitor reimbursement progress and trial uptake.